Has David Domenichini, MD received payments from drug or device companies?

Yes. Drug and device makers reported $220,302 in general payments to David Domenichini, MD across 1,152 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Domenichini, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Domenichini, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Domenichini, MD

Endocrinology, Diabetes & Metabolism · Bloomfield, CTNPI 1225004922

Payments from drug & device makers

$220,302in general payments, 2019–2025

Across 1,152 payments — averaging $191.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$122K
Dexcom, Inc.$46K
AstraZeneca$14K
AbbVie$8K
Johnson & Johnson$7K
Merck$7K
plus $17K from 53 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	390	$122,436
Dexcom, Inc.	96	$45,669
AstraZeneca(2 entities)	49	$13,784
AbbVie(2 entities)	51	$8,154
Johnson & Johnson	19	$6,699
Merck	19	$6,596
Corcept Therapeutics	23	$3,683
Amgen(2 entities)	62	$1,559
Sanofi-aventis U.S. LLC	33	$1,456
Lilly USA, LLC	70	$1,419
Abbott	63	$1,253
Bayer	22	$1,032
Valeritas, Inc.	4	$820
Boehringer Ingelheim	30	$713
Xeris Pharmaceuticals, Inc.	32	$678
Mannkind Corporation	9	$368
Antares Pharma, Inc.	14	$367
Amarin Pharma, Inc.	25	$331
Amneal Pharmaceuticals LLC	27	$319
Senseonics, Incorporated	5	$240
IBSA Pharma Inc.	12	$217
Ascendis Pharma Endocrinology Inc	5	$189
Tandem Diabetes Care, Inc.	6	$187
Novartis	3	$178
Biohaven Pharmaceutical Holding Company Ltd.	3	$169
Cequr Corporation	4	$165
Embecta Corp.	5	$152
Aytu Biopharma, Inc.	8	$129
Biohaven Pharmaceuticals, Inc.	1	$116
Eisai Inc.	6	$115
Insulet Corporation	4	$86
BD	4	$74
Pfizer	4	$73
Ascensia Diabetes Care US Inc.	4	$67
Radius Health, Inc.	3	$63
Medtronic	2	$60
Madrigal Pharmaceuticals	3	$55
Kyowa Kirin, Inc.	2	$46
Sequel Med Tech, LLC	2	$46
Esperion Therapeutics, Inc.	2	$43
BETA Bionics, Inc.	1	$42
Intra-sana Laboratories	2	$42
Recordati_rare_diseases_inc.	2	$39
Ultragenyx Pharmaceutical Inc.	2	$38
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$35
Companion Medical, Inc.	2	$33
Currax Pharmaceuticals LLC	2	$31
Kowa Pharmaceuticals America, Inc.	2	$28
Halozyme Inc	1	$24
Exact Sciences	1	$24
Vivus LLC	1	$20
GSK	1	$20
Shire North American Group Inc	1	$19
Lifescan, Inc.	1	$19
Azurity Pharmaceuticals, Inc.	1	$18
Acerus Pharmaceuticals Corporation	1	$18
EUSA Pharma (US) LLC	1	$17
Gilead	1	$16
Endo Pharmaceuticals Inc.	1	$14

How this compares

$220,302 in reported general payments places this provider in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Medicare billing

Part B allowed, 2024

$112,035

Medicare patients

407

Services billed

882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Bloomfield

Ania JastreboffNew Haven$2.2M
Ilja HulinskyBridgeport$1.6M
Gerald ShulmanNew Haven$1M
Karl InsognaNew Haven$903K
Clemens BergwitzNew Haven$735K
Egils BogdanovicsTorrington$608K
Robert ObersteinHartford$516K
Fadi Al-KhayerStorrs$489K
Silvio InzucchiNew Haven$461K
Francis WilsonNew Haven$415K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →